Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $62.5 million, a decrease of 9% compared to the prior year period, primarily due to a shift in revenue mix towards lower-priced products [21] - Gross margin was 80.6% in Q4 2025, slightly down from 80.7% in Q4 2024 [21] - Total operating expenses increased to $56.3 million in Q4 2025 from $55.7 million in Q4 2024, reflecting restructuring charges and increased litigation expenses [21] - The net loss for Q4 2025 was $9.4 million, or $0.15 per share, compared to a net loss of $0.5 million, or $0.01 per share, in Q4 2024 [22] - Adjusted EBITDA for Q4 was $6.2 million, down from $11.1 million in Q4 2024, while the full year 2025 Adjusted EBITDA loss was $3.9 million, a 64% improvement over the prior year [22][23] - Cash usage for the full year 2025 was $27.3 million, a 46% reduction compared to $50.5 million in 2024 [23] Business Line Data and Key Metrics Changes - The company has expanded its bunion procedure offerings, now addressing virtually 100% of surgeons' technique preferences for bunion correction [5] - New bunion systems launched in 2025 are expected to significantly increase market penetration and procedure volume growth [10][19] - Over 25% of the surgeon base has incorporated one or more of the new bunion systems into their practice, with Q4 procedure volume growth exceeding mid-single-digit rates [13][19] Market Data and Key Metrics Changes - The overall foot and ankle market was reported to be soft in 2025, with deferrals of elective procedures impacting case volumes [27] - The company anticipates that case volume growth will continue to be offset by product ASP mix-related headwinds in the first half of 2026 [28] - The company expects to capture a larger share of the market with new product launches and improved sales strategies [19][28] Company Strategy and Development Direction - The company is focused on leveraging its existing customer base to drive adoption of new products and expand its serviceable total addressable market (TAM) [10] - Plans for 2026 include launching new products that are expected to enhance market share and profitability [16][19] - The company aims to continue improving its profitability and reducing cash burn, with a target of a 50% reduction in cash usage for 2026 compared to 2025 [23][24] Management's Comments on Operating Environment and Future Outlook - Management noted that broader economic conditions and softer consumer sentiment continue to impact the business environment [7] - The outlook for full year 2026 revenue is projected to be in the range of $200 million to $212 million, representing a decline of 6% to 0% compared to 2025 [8][23] - Management expressed confidence in the strategies in place to restore top-line revenue growth and improve profitability [6][19] Other Important Information - The company has expanded its active surgeon base from nearly 1,300 users in 2020 to over 3,300 users in 2025 [18] - The company has entered the biologics market with new offerings, which are expected to enhance revenue without negatively impacting margins [31] Q&A Session Summary Question: Market conditions and growth outlook - Management acknowledged that the foot and ankle market was soft in 2025, with case deferrals impacting overall surgical volume, but noted an increase in Q4 case volumes [27][28] Question: Impact of biologics on operating margins - Management indicated that the expansion into biologics is expected to provide additional revenue without negatively impacting margins [31] Question: Product development timelines and surgeon feedback - Management confirmed that new products like SuperBite and SpeedXM have been in development for about 18 months and received positive feedback from surgeons [36][38] Question: Balancing sales force focus with new product offerings - Management emphasized that the sales force remains focused on bunion-related products while also addressing adjacent procedures to meet surgeon demand [54][55] Question: Cash flow outlook and cost management - Management detailed initiatives to reduce cash burn and improve profitability, including lower operating expenses and capital expenditures in 2026 [64][66]

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $62.5 million, a decrease of 9% compared to the prior year period, primarily due to a shift in revenue mix towards lower-priced products [19] - Gross margin was 80.6% in Q4 2025, slightly down from 80.7% in Q4 2024 [19] - Total operating expenses increased to $56.3 million in Q4 2025 from $55.7 million in Q4 2024, reflecting restructuring charges and increased litigation expenses [19] - Net loss for Q4 2025 was $9.4 million, or $0.15 per share, compared to a net loss of $0.5 million, or $0.01 per share, in Q4 2024 [20] - Full year 2025 Adjusted EBITDA loss was $3.9 million, a 64% improvement over the prior year [20] - Cash usage for the full year 2025 was $27.3 million, a 46% reduction compared to $50.5 million in 2024 [21] Business Line Data and Key Metrics Changes - The company has transitioned from a Lapiplasty-focused company to a comprehensive bunion solutions provider, launching multiple new bunion procedure innovations [4] - The new bunion systems are expected to effectively double the accessible market, targeting a significant portion of the 450,000 annual bunion procedures in the U.S. [9] - Over 25% of the surgeon base has incorporated one or more of the new bunion systems into their practice, with Q4 procedure volume growth increasing over mid-single-digit rates achieved in Q3 [11][18] Market Data and Key Metrics Changes - The foot and ankle market was reported to be unusually soft in 2025, with deferrals of cases impacting overall bunion surgical volume [26] - The company expects to capture market share despite the softness, with an anticipated increase in case volume in 2026 [26] - The outlook for full year 2026 revenue is projected to be in the range of $200 million-$212 million, representing a decline of 6%-0% compared to full year 2025 [21] Company Strategy and Development Direction - The company aims to leverage its existing customer base to drive adoption of new bunion product launches and expand its product offerings to grow wallet share [8] - The strategy includes advancing the Lapiplasty technology and introducing new products like the Lapiplasty Lightning and SpeedTMT implants [12][14] - The company plans to expand its biologics market presence with new offerings, which are expected to enhance revenue without negatively impacting margins [15][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing headwinds related to broader economic conditions and softer consumer sentiment, which are expected to persist into 2026 [5] - The company anticipates a reduction in cash usage of approximately 50% for full year 2026 compared to 2025, supported by a strong balance sheet [22] - Management expressed confidence in the strategies in place to drive market share gains and improve profitability [18] Other Important Information - The company has expanded its active surgeon base from nearly 1,300 users in 2020 to over 3,300 users in 2025, indicating strong growth in customer engagement [17] - The company plans to launch additional products in 2026 that are expected to expand its total addressable market by an estimated $300 million [16] Q&A Session Summary Question: Thoughts on the softness in the foot and ankle market - Management noted that 2025 was a softer year due to case deferrals, but they are seeing an increase in Q4 case volumes, indicating market share gains [26] Question: Impact of biologics portfolio on operating margins - Management expressed optimism that the expansion of the biologics portfolio would provide additional revenue without negatively impacting margins [30] Question: Details on new products and their development - The SuperBite screws and SpeedXM midfoot plating system have been in development for about 18 months and are expected to enhance the product offering significantly [35][36] Question: How to balance the focus of the sales force with new products - Management emphasized that the sales force is trained to focus on the bunion segment while also addressing adjacent procedures, ensuring they meet customer demands [54] Question: Long-term growth expectations - Management believes that with the expanded product portfolio and focus on the bunion market, they can achieve at least mid-single-digit growth, potentially higher with market share gains [73]

Financial Data and Key Metrics Changes - The company reported third quarter revenues of $50.2 million, representing an 11% growth over the third quarter of 2024 and a 49% improvement in adjusted EBITDA compared to the prior year [4][17] - Gross margin decreased to 79.1% in Q3 2025 from 80.1% in Q3 2024 [17] - The net loss for the third quarter was $16.3 million, or $0.26 per share, which is a 6% increase in net loss compared to $15.4 million, or $0.25 per share, in Q3 2024 [18] - Year-to-date net loss decreased by 10% to $49.6 million compared to $55.2 million for the same period in 2024 [18] - Total liquidity as of September 30, 2025, was $80.6 million, down from $90.7 million at the end of Q2 [19] Business Line Data and Key Metrics Changes - The company has expanded its product portfolio to include three new bunion correction systems, aiming to address nearly 100% of surgeon preferences for bunion correction [5][6] - Case volume growth was mid-single digits compared to the prior year, but below original expectations, largely driven by new bunion systems with lower average selling prices (ASPs) [10] - Sales to a limited number of stocking distributors contributed approximately $6 million in the third quarter, which is not expected to recur at the same levels in future quarters [12] Market Data and Key Metrics Changes - A survey indicated that surgeon customers reported a 7% decrease in bunion surgical volumes year-to-date through October compared to the same period last year [11] - Broader economic conditions and softer consumer sentiment have led to deferrals of elective bunion procedures, impacting case volumes [8][11] Company Strategy and Development Direction - The company is transitioning from a single technology focus to a comprehensive bunion solutions provider, with plans to capture market share in minimally invasive osteotomies and MTP fusion markets [5][9] - The strategy includes enhancing the sales team's capabilities and expanding the product portfolio to drive market share gains and improve profitability [13][15] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in the current growth trajectory and revised the full-year revenue outlook to $211 million-$213 million, reflecting only 1%-2% growth compared to 2024 [8][20] - The company plans to continue focusing on training existing customers and onboarding new surgeons to drive adoption of new products [13][22] Other Important Information - The company is taking actions to control costs and improve profitability, with a focus on reducing cash burn in 2026 [16][20] - The company has appointed a new Chief Commercial Officer and expanded its sales team to enhance market presence [6] Q&A Session Summary Question: Can you talk about the softness in the core Lapiplasty business? - Management acknowledged a trend towards minimally invasive osteotomies but emphasized the importance of Lapiplasty for significant bunion deformities, stating efforts to capture market share in this area [24][25] Question: What does the guidance imply for Q4 and 2026? - Management refrained from providing specific guidance for 2026 but expressed optimism about case volume growth and the reception of new products [26][27] Question: Has there been an acceleration in the shift away from Lapiplasty? - Management confirmed a trend towards minimally invasive procedures but highlighted ongoing efforts to capture market share with new technologies [30][31] Question: How will the company recoup deferred procedures next year? - Management indicated that improved consumer sentiment and enhanced engagement with new products would help capture a larger share of patients returning for surgery [38]

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. alleging securities fraud affecting investors between May 8, 2023, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Treace Medical Concepts, Inc. made false statements regarding the impact of competition on the demand for its primary product, the 3D bunion correction system, "Lapiplasty" [2]. - It is alleged that due to competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2]. - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Treace Medical Concepts, Inc. (NASDAQ: TMCI) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Allegations include that competition negatively impacted the demand for the Lapiplasty system, leading to a decline in Treace Medical's revenue [3]. - The company needed to accelerate plans for an alternative product to osteotomy due to these challenges [3]. - Defendants' positive statements about the company's business and prospects were claimed to be materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 10, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action securities lawsuit has been filed against Treace Medical Concepts, Inc. due to alleged securities fraud impacting investors between May 8, 2023, and May 7, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Treace Medical Concepts concealed the impact of competition on the demand for its primary product, the 3D bunion correction system known as "Lapiplasty" [2] - As a result of competitive pressures, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [2] - Defendants allegedly made materially misleading positive statements regarding the company's business, operations, and future prospects [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until June 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Financial Performance - Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to a range of $201 million to $211 million [3] - Following this announcement, Treace Medical's stock price fell by $6.95, nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5]

Core Viewpoint - Treace Medical Concepts, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its primary product, the 3D bunion correction system, "Lapiplasty" [3]. Group 1: Allegations and Impact - The lawsuit claims that competition negatively affected the demand and utilization of the Lapiplasty system [3]. - As a result of the competitive pressure, Treace Medical's revenue declined, prompting the company to expedite plans for an alternative product to osteotomy [3]. - The defendants' positive statements about the company's business and prospects were allegedly misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - The class period for the lawsuit is from May 8, 2023, to May 7, 2024 [3]. - Shareholders who purchased TMCI shares during this period are encouraged to register for the class action, with a deadline set for June 10, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Treace Medical Concepts, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from May 8, 2023, to May 7, 2024 [1] Group 1: Allegations and Impact - The complaint alleges that competition negatively affected the demand and utilization of Treace Medical's primary product, the 3D bunion correction system known as "Lapiplasty" [1] - As a result of the competition, Treace Medical's revenue declined, prompting the company to accelerate plans for an alternative product to osteotomy [1] - The defendants' positive statements about the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [1] Group 2: Class Action Details - Shareholders who purchased shares of TMCI during the specified class period are encouraged to register for the class action, with a deadline of June 10, 2025, to seek lead plaintiff status [2] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2] - Participation in the case incurs no cost or obligation for the shareholders [2] Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit, fraud, and illegal business practices [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3]

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc for alleged securities fraud and unlawful business practices [2][3]. Group 1: Lawsuit Details - The lawsuit involves Treace Medical and certain officers and/or directors accused of engaging in securities fraud [2]. - Investors who purchased Treace Medical securities during the Class Period have until June 10, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Financial Performance - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from a range of $220 million to $225 million down to $201 million to $211 million [3]. - The company cited competition from minimally invasive osteotomy and Lapiplasty "knockoffs" as headwinds affecting Lapiplasty growth [3]. Group 3: Stock Market Reaction - Following the revenue guidance cut, Treace Medical's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [4].